Seribantumab (INN; development code MM-121) is a monoclonal antibody designed for the treatment of cancer.Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association. It binds to extracellular domain of HER3 blocking NRG1 binding and thereby preventing the activation of the receptor.
This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.
References